[Clinical trial of a combined oral contraceptive with low estrogen dose (author's transl)].
309 women took a combined oral contraceptive (0.04 mg ethinylestradiol and 2.0 mg lynestrol) in 1876 cycles under clinical supervision. The preparation was extremely well tolerated. Pregnancy did not occur; In 57 cases the administration of the tablets was concluded prematurely, but side effects were given as the reason for this discontinuation of the contraceptive in only 6.5% of the cases. Withdrawal bleeding lasted 3.9 days in the control cycle and 3.7 days in the 6th treatment cycle. Breakthrough bleeding occurred in 0.3% of the women.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003276:Contraceptives, Oral / Q000009:adverse effects; D003278:Contraceptives, Oral, Hormonal; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004347:Drug Interactions; D004967:Estrogens / Q000008:administration & dosage*; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D008234:Lynestrenol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D013923:Thromboembolism / Q000139:chemically induced
D003276:Contraceptives, Oral; D003278:Contraceptives, Oral, Hormonal; D004338:Drug Combinations; D004967:Estrogens; D004997:Ethinyl Estradiol; D008234:Lynestrenol
Klinische Untersuchung eines kombinierten oralen Kontrazeptivums mit niedriger Ostrogendosis